DelveInsight’s ‘Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Follicular Lymphoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
What is Follicular Lymphoma?
Follicular lymphoma, a B-cell lymphoma, is the second most common type of low-grade non-Hodgkin lymphoma (NHL). The transformation of a B-cell characterizes it into a malignant cell. Abnormal, uncontrolled growth and proliferation of malignant B-cells can lead to enlargement of specific lymph node regions; involvement of other lymphatic tissues such as the spleen or bone marrow; and spread to other bodily tissues and organs.
What are Follicular Lymphoma causes?
Follicular Lymphoma causes are not known. Unlike some cancers, they are not passed down in families. In some cases, radiation or cancer-causing chemicals, or certain infections, may be a cause. But other times there is no known cause.
What are the symptoms of Follicular Lymphoma?
Follicular Lymphoma symptoms include painless swelling of the lymph nodes in your neck, groin, stomach, or armpits, shortness of breath, fatigue, night sweats, and weight loss.
How Follicular Lymphoma affected population?
Follicular Lymphoma Epidemiology
- According to DelveInsight’s analysis, the total prevalent population of Follicular Lymphoma in seven major markets was 33,363 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).
- Among all the seven major markets, the United States accounts for the highest number of Follicular Lymphoma cases.
- In the US, the Follicular Lymphoma cases were 14,329 in 2017. Moreover, the grade-specific cases of Follicular Lymphoma were highest among grade I and were reported to be 5,198 cases.
To know more, request sample pages @Follicular Lymphoma Market Landscape
Follicular Lymphoma Market Outlook
According to DelveInsight, the Follicular Lymphoma market size is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounts for the largest Follicular Lymphoma market size with USD 799 million in 2017, while Spain had the smallest market size of Follicular Lymphoma with USD 56 million in 2017.
What are the present Follicular Lymphoma market drivers?
Changing standards of care, increasing opportunities and family history aims at driving the market growth.
What are the Follicular Lymphoma market barriers?
Clinical heterogeneity, economic burden of the disease and adverse effects of the therapies are some limitations to the Follicular Lymphoma Market Growth.
Which are the leading companies in Follicular Lymphoma market?
Key Players such as Epizyme, Kite Pharma, Novartis, Roche, Regeneron, TG therapeutics, MEI Pharma, Incyte Corporation, Bayer Health, Verastem Oncology, Gilead Sciences, Xynomics Pharmaceuticals, Bristol Myeres, Takeda Oncology, and others are the leading companies in Follicular Lymphoma market.
Request sample pages for more information on Follicular Lymphoma Market Size
Table of contents
1. Key Insights
2. Executive Summary of Follicular Lymphoma
3. SWOT Analysis for Follicular Lymphoma
4. Follicular Lymphoma Market Overview at a Glance
4.1. Market Share (%) Distribution of Follicular Lymphoma in 2018
4.2. Market Share (%) Distribution of Follicular Lymphoma in 2030
5. Disease Background and Overview
5.1. Introduction
5.2. Types of Follicular Lymphoma
5.3. Sign and Symptoms
5.4. Causes
5.5. Staging and Grading
5.6. Genetic Landscape of Follicular Lymphoma
5.7. Pathophysiology
5.8. Diagnosis
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM Total Incident Patient Population of Follicular Lymphoma
7. Country Wise-Epidemiology of Follicular Lymphoma
7.1. Assumptions and Rationale – 7MM
7.2. The United States
7.2.1. Total Incident Cases of Follicular Lymphoma in the United States
7.2.2. Grade-specific Cases of Follicular Lymphoma in the United States
7.2.3. Age-specific Cases of Follicular Lymphoma in the United States
7.2.4. Stage-specific Cases of Follicular Lymphoma in the United States
7.3. EU5
7.3.1. Germany
7.3.1.1. Total Incident Cases of Follicular Lymphoma in Germany
7.3.1.2. Grade-specific Cases of Follicular Lymphoma in Germany
7.3.1.3. Age-specific Cases of Follicular Lymphoma in Germany
7.3.1.4. Stage-specific Cases of Follicular Lymphoma in Germany
7.3.2. France
7.3.2.1. Total Incident Cases of Follicular Lymphoma in France
7.3.2.2. Grade-specific Cases of Follicular Lymphoma in France
7.3.2.3. Age-specific Cases of Follicular Lymphoma in France
7.3.2.4. Stage-specific Cases of Follicular Lymphoma in France
7.3.3. Italy
7.3.3.1. Total Incident Cases of Follicular Lymphoma in Italy
7.3.3.2. Grade-specific Cases of Follicular Lymphoma in Italy
7.3.3.3. Age-specific Cases of Follicular Lymphoma in Italy
7.3.3.4. Stage-specific Cases of Follicular Lymphoma in Italy
7.3.4. Spain
7.3.4.1. Total Incident Cases of Follicular Lymphoma in Spain
7.3.4.2. Grade-specific Cases of Follicular Lymphoma in Spain
7.3.4.3. Age-specific Cases of Follicular Lymphoma in Spain
7.3.4.4. Stage-specific Cases of Follicular Lymphoma in Spain
7.3.5. The United Kingdom
7.3.5.1. Total Incident Cases of Follicular Lymphoma in the United Kingdom
7.3.5.2. Grade-specific Cases of Follicular Lymphoma in the United Kingdom
7.3.5.3. Age-specific Cases of Follicular Lymphoma in the UK
7.3.5.4. Stage-specific Cases of Follicular Lymphoma in the UK
7.4. Japan
7.4.1. Total Incident Cases of Follicular Lymphoma in Japan
7.4.2. Grade-specific Cases of Follicular Lymphoma in Japan
7.4.3. Age-specific Cases of Follicular Lymphoma in Japan
7.4.4. Stage-specific Cases of Follicular Lymphoma in Japan
8. Treatment
9. Guidelines
9.1. NCCN Guidelines for Patient with Follicular Lymphoma
9.2. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: Newly diagnosed and relapsed follicular lymphoma
9.3. Japanese Society of Hematology (JSH) practical guidelines for Follicular lymphoma
10. Unmet Needs
11. Organizations contributing toward Follicular Lymphoma
12. Patient Journey
12.1. A Journey through follicular lymphoma
12.2. Patient Journey: General
13. Case Reports
13.1. Patient Case Study: From Follicular Lymphoma to DLBCL
13.2. Diagnostic Workup for Follicular Lymphoma
13.3. A case study of t(14;22)(q32;q11) involving immunoglobulin heavy and light chain in follicular lymphoma
14. Marketed Therapies
14.1. Tazverik: Epizyme
14.1.1. Product Description
14.1.2. Other Development Activities
14.1.3. Clinical Development
14.1.4. Safety and Efficacy
14.2. Aliqopa: Bayer Healthcare Pharmaceuticals
14.2.1. Product Description
14.2.2. Other Development Activities
14.2.3. Clinical Development
14.2.4. Safety and Efficacy
14.3. Copiktra: Verastem Oncology
14.3.1. Product Description
14.3.2. Other Development Activities
14.3.3. Clinical Development
14.3.4. Safety and Efficacy
14.4. Zydelig: Gilead Sciences
14.4.1. Product Description
14.4.2. Other Development Activities
14.4.3. Clinical Development
14.4.4. Safety and Efficacy
15. Combinational Therapies: Marketed
16. Emerging Therapies
16.1. Abexinostat: Xynomic Pharmaceuticals, Inc.
16.1.1. Product Description
16.1.2. Other Development Activities
16.1.3. Clinical Development
16.1.4. Safety and Efficacy
16.2. Umbralisib: TG Therapeutics
16.2.1. Product Description
16.2.2. Other Development Activities
16.2.3. Clinical Development
16.2.4. Safety and Efficacy
16.3. ME-401: MEI Pharma
16.3.1. Product Description
16.3.2. Other Development Activities
16.3.3. Clinical Development
16.3.4. Safety and Efficacy
16.4. Odronextamab: Regeneron Pharmaceuticals
16.4.1. Product Description
16.4.2. Other Development Activities
16.4.3. Clinical Development
16.4.4. Safety and Efficacy
16.5. Parsaclisib: Incyte Corporation
16.5.1. Product Description
16.5.2. Other Development Activities
16.5.3. Clinical Development
16.5.4. Safety and Efficacy
16.6. Kymriah: Novartis
16.6.1. Product Description
16.6.2. Other Development Activities
16.6.3. Clinical Development
16.7. Yescarta: Kite Pharma
16.7.1. Product Description
16.7.2. Other Development Activities
16.7.3. Clinical Development
16.7.4. Safety and Efficacy
16.8. Nivolumab: Bristol-Myers Squibb
16.8.1. Product Description
16.8.2. Other Development Activities
16.8.3. Clinical Development
16.8.4. Safety and Efficacy
16.9. Ixazomib – Takeda Oncology
16.9.1. Product Description
16.9.2. Other Development Activities
16.9.3. Clinical Development
16.9.4. Safety and Efficacy
17. Emerging Combinational Therapies
17.1. Ibrutinib + Rituximab
17.2. Umbralisib + Ublituximab + Bendamustine
17.3. Zanubrutinib + Obinutuzumab
18. Other Promising Therapies
18.1. Atezolizumab: Roche
18.1.1. Product Description
18.1.2. Other Development Activities
18.1.3. Clinical Development
18.1.4. Safety and Efficacy
18.2. Pembrolizumab: Merck
18.2.1. Product Description
18.2.2. Other Development Activities
18.2.3. Clinical Development
18.2.4. Safety and Efficacy
18.3. Venetoclax – AbbVie/Genentech
18.3.1. Product Description
18.3.2. Other Development Activities
18.3.3. Clinical Development
18.3.4. Safety and Efficacy
18.4. Betalutin: Nordic Nanovector ASA
18.4.1. Product Description
18.4.2. Other Development Activities
18.4.3. Clinical Development
18.4.4. Safety and Efficacy
18.5. Tenalisib: Rhizen Pharmaceuticals
18.5.1. Product Description
18.5.2. Other Development Activities
18.5.3. Clinical Development
18.5.4. Safety and Efficacy
19. Follicular Lymphoma: Seven Major Market Analysis
19.1. Key Findings
19.2. Market Size of Follicular Lymphoma in 7MM
20. Market Outlook
20.1. 7MM Market Outlook
20.2. United States Market Size
20.3. EU-5 Countries: Market Outlook
20.3.1. Germany
20.3.2. France
20.3.3. Italy
20.3.4. Spain
20.3.5. United Kingdom
20.4. Japan: Market Outlook
20.4.1. Total Market Size of Follicular Lymphoma
20.4.2. Market Size of Follicular Lymphoma by Therapies
21. Market Drivers
22. Market Barriers
23. Market Access and Reimbursement
24. Appendix
24.1. Bibliography
24.2. Report Methodology
25. DelveInsight Capabilities
26. Disclaimer
27. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/